The Touchstone Effect

1
The Touchstone Effect

• The Impact of Pre-grant Opposition on Patents

by Feroz Ali Khader, Advocate feroz.ali.k_at_gmail.c
om 9444217156
2
A story in three parts

• Long ago, before the continent of Australia was
  discovered, the old world knew and believed that
  all swans were white.
• It was in Australia that the first black swan was
  sighted.
• The single sighting invalidated a general
  statement derived from millennia of confirmatory
  sightings of millions of white swans.

3
Part 1 Black Swan

• What is a Black Swan?
• Nassim Taleb in his book The Black Swan The
  Impact of the Highly Improbable stretches the
  idea of Black Swan to define events that share
  the following three characteristics
• It is an outlier an event that lies outside the
  realm of regular expectations.
• It carries an extreme impact.
• It can be predicted only after it happens.

4
Part 1 Black Swan

• In other words, a Black Swan
• Is a rarity
• Has extreme impact and
• Has retrospective predictability
• Everything of importance around you will qualify
  for a Black Swan
• 9/11 is a Black Swan So is Google same can be
  said about the end of Soviet Union and the
  spread of Internet.

5
Part 1 Black Swan

• This combination of low predictability and large
  impact makes the Black Swan a great puzzle.
• Black Swan logic makes what you don't know far
  more relevant than what you do know.
• Black Swans exist in all businesses.
• It is the next BIG thing, the Killer
  Innovation the wonder drug which is new,
  non-obvious and cannot be conceived by others.
• More importantly, Black Swans dominate the
  pharmaceutical industry.

6
Part 2 Black Swan Innovation

• Innovation is an effort to create purposeful
  focused change in an enterprises economic or
  social potential Peter F. Drucker
• Innovations could lead to patentable inventions
  and vice-versa.
• Innovation refers the process of bringing out
  patentable inventions.
• Technological Innovation can be
• Radical innovation Eg. Post-it
• Incremental innovation Eg Colour, Shapes

7
Radical Innovation

• Very rare and by nature unpredictable true
  Black Swans
• Radical innovation in pharmaceuticals have low
  predictability but high impact they become
  blockbusters.
• Blockbusters are drugs with sales of over a
  billion dollars a year
• Pfizers Lipitor, Novartis Gleevec etc

8
Serendipitous Discoveries

• Every serendipitous discovery qualifies for a
  radical or Black Swan Innovation.
• Penicillin was discovered serendipitously.
• The same is true about Pfizers anti-impotence
  drug, Viagra (sildenafil citrate), which was
  initially used for treating hypertension and
  angina pectoris.
• Minoxidils hair growing properties were noticed
  fortuitously while treating some bald patients
  for hypertension.
• The anaesthetic use of nitrous oxide (laughing
  gas) and ether were discovered accidentally.

9
Incremental innovation

• Are the minor changes and developments made to a
  radical innovation
• Common industrial practice to invent a radical
  innovation and to develop it further
  incrementally. Eg Detergents, Dentifrices and
  Diapers PG can be called the 3(d) Company.
• And Section 3(d) regulates the patenting of
  incremental innovations

10
Me too

• Me too drugs are the incarnations of
  incremental innovation.
• High-priced editions of existing drugs
  variations of older drugs already in market
• Nexium (www.purplepill.com)
• Six best-selling statins Mevacor, Lipitor,
  Zocor, Pravachol, Lescol and Crestor.

11
Looking out for blockbusters

• Blockbusters means easy profit the lure of huge
  pay offs
• Lipitor earns Pfizer an annual revenue of 13
  Billion.
• AstraZenecas Prilosec (for heartburn) earned a
  revenue of 6 billion in 2001.

12
How innovative is the industry?

• The output of innovative drugs have been far and
  few
• The real source of innovation are the academic
  institutions, small biotech companies and public
  funded research organisation.
• AZT, the first AIDS drug was developed by
  National Cancer Institute and Duke University
  later licensed to GSK

13
How innovative is the industry?

• Taxol (paclitaxel), leading cancer drug,
  developed by National Cancer Institute and
  Florida State University licensed to
  Bristol-Myers Squibb
• Amgens Epogen was developed by University of
  Chicago and Columbia.
• Gleevec benefitted from NIH funded university
  researcher

14
Part 3 Painting the Swan Black

• The pharmaceutical industry has a tendency to
  paint a white swan black or to repaint a faded
  old Black Swan
• Opposition acts as a check on this phenomenon
• With the pipeline of new drugs dwindling, the
  industry now focuses on packaging what is known
  as Black Swans

15
When pipelines dwindle

• New Drugs Approved by the US FDA between 1996 and
  2004
• Painting Swans Black is a consequence of the
  industry reality of fewer new drugs

Year NDA NME
2004 25 17
2003 14 9
2002 11 7
2001 10 7
2000 20 9
16
When Blockbusters go off-patent

• Pharmaceutical companies lose huge part of the
  market share when their patents expire.
• Eli Lillys patent on Prozac expired in 2001.
• AstraZenecas patent for Prilosec (the original
  purple pill) expired in 2001 when the drug had a
  revenue of 6 billion in annual sales. Replaced
  by Nexium
• Bristol-Myers Squibb lost its best seller
  Glucophage.
• Schering-Plough lost Claritin and tried to
  replace it unsuccessfully with Clarinex.

17
Opposition as a touchstone

• Opposition acts as a touchstone for checking the
  quality of patents or as sandpaper to check the
  plumage of Swans
• It helps in the development of a strong patent
  system where only the right inventions get
  rewarded and the wayward gets rejected
• Helps the Patent Office to take informed
  decisions on grant

18
What is Pre-grant Opposition?

• Peer-initiated challenge mechanism under the
  Patents Act.
• Challenge initiated before the grant at the
  Patent Office.
• Administrative in nature and not judicial.
• Helps the patent office to overcome information
  asymmetry
• The purpose of opposition proceedings is to give
  a competitor/interest groups the opportunity of
  opposing unjustified protective rights.

19
Pre-grant Opposition is

• risk avoidance.
• Helps you avoid the risk of facing an expensive
  infringement suit.
• In-house procedure keeps you in control
• The most important part of patent enforcement, ie
  filing suits for infringement is an activity that
  is outsourced and involves a gamut of different
  and highly unpredictable players. Opposition
  helps you to decide the course of action.

20
Why Pre-grant Opposition is important.

• A patent application will disclose technical
  information about the area in which the invention
  is claimed.
• Patent Offices around the world have difficulties
  in keeping pace with the rapid advancement of
  technology in all areas of science.
• The knowledge about an earlier invention or a
  disclosure more likely to come from the
  competitors who have expertise in that particular
  field of technology in which the invention is
  claimed.

21
Its relevance from a systemic viewpoint

• The device of opposition by competitors is a
  means to equip the Patent Office with information
  that may not be available to it.
• Opposition proceedings will be significant in
  determining the grant of patents for the
  applications currently pending before the Patent
  Office.
• In the case of pharmaceutical patents, opposition
  proceedings will play an important role not only
  in the development of patent law but also in the
  future course of the pharmaceutical industry.

22
Efficient Procedure

• Time-bound proceedings
• The Act and the Rules stipulate specific
  time-limits for completing the opposition process
  efficiently. (Rule 55)
• Summary proceedings
• The underlying principle the opposition procedure
  is of early and complete presentation of the
  parties cases as opposed to the piecemeal and
  tardy introduction of arguments and supporting
  evidence.

23
Cost-Effective Procedure

• A comparatively straightforward procedure
• Results in quick disposal on merits thereby
  reducing the costs incurred in contesting the
  proceedings.
• Trial and appreciation of evidence in the
  traditional manner in which it happens in the
  courts of law do not occur in opposition
  proceedings.
• No fee stipulated for filing a pre-grant
  opposition.
• But, there could be costs when opposition fails.

24
Time-bound Procedure

• Representation for opposition should be filed
  within six months from the date of publication of
  application (safe period)
• Publication of the application under section 11 A
• Applicant has three months time to file response.
• Hearing signifies the final step in a pre-grant
  opposition, after which the Controller gives his
  decision.
• Controller shall give the decision within one
  month after the completion of hearing.

25
The Rs.120 Crore (or more) Question

• Do you need a strategy on opposing patents?
• the company lost about Rs 120 crore in sales
  because of the delay in launching the Flame
• - Mr Venu Srinivasan, MD, TVS
• TVS found out that it needed one after Bajaj sued
  it for patent infringement of its twin-spark plug
  technology.
• The experts at TVS knew about Bajajs patent and
  yet did not oppose.
• Opposition doesnt cost much. But not initiating
  one does.

26
Bajaj Auto Ltd

• Bajajs taking TVS to task over its spark plug
  patent.
• Bajaj seems to have a strategy on opposition so
  far opposed applications
• Patent No.176906 (223/BOM/ 1993) of Automotive
  Research Asso. of India, (Failed)
• Patent No. 176968 (419/BOM/ 1992) of Greaves
  Cotton Co Ltd (Succeeded)
• Patent No. 184001 of Piaggio (Failed)

27
Hindustan Unilever

• HLL ( now HU) also seems to have a strategy on
  opposition
• Patent No.190644 (102/BOM/1998) by Alphacon
  Containers Pvt. Ltd (Failed)
• Patent No.198399 (931/CHE/2003) Post-grant
  Opposition (Failed) but patent amended.

28
PG

• Unilevers global rival appears to be taking
  Unilever to the task
• Patent No. 174429 (100/BOM/92) of HLL opposed by
  PG Far East Inc (US Company) Succeeded
• Patent No. 174537 (237/BOM/1992) of HLL opposed
  Succeeded
• Patent No.174044 (249/BOM/1991) of HLL Failed
• Patent No. 176112 (303/BOM/92) of HLL Succeeded
• Patent No.173958 (316/BOM/I99I) of HLL Failed-
  Patent amended.

29
Ranbaxy

• Ranbaxy (Soon Daiichi Sankyo) has an open
  strategy on challenging patents.
• Patent No. 85/DEL/1995 of Eli Lilly Co -
  partially succeeded only process patents
  granted
• Patent No. 190/MAS/1998 of Roche Succeeded
• Patent No. 1440/MAS/1998 of Novartis Succeeded
• Patent No. 1602/MAS/1998 of Novartis Gleevec
  case Succeeded
• IN/PCT/2000/00084/CHE of Pfizer Failed Patent
  amended.
• IN/PCT/2001/00788/CHE of Pfizer Failed

30
The Role of Strategic Oppositions

• Helps you to keep track of competition
• Patents keeps you informed about how others are
  growing and a strategy will help you to find your
  place
• Increases your market share whenever a patented
  drug is kept out of market
• Gives reliable information on your RD efforts
  Where you put your money

31
Please visit

• The web page of my new book
• The Touchstone Effect The Impact of Pre-grant
  Opposition on Patents
• by LexisNexis Butterworths Wadhwa Nagpur
• www.thetouchstoneeffect.blogspot.com
• or simple Google the words
• Touchstone Effect for more info